ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Jun 28, 2018 07:00 JST
Source:
Novotech Health Holdings Pte Ltd
Novotech at DIA18 announces Asia Partnerships on Target to Reach 1.4 Bil Patients
BOSTON, Jun 28, 2018 - (ACN Newswire) - Asia-Pacific CRO Novotech announced at DIA18 (24-28 June, Boston Convention and Exhibition Center) that it has signed Memorandums of Understanding (MOUs) with five of the leading medical institutions in the region. The MOU partnership program is designed to give Novotech clients access to an additional 1.4 billion patients, and specialist investigators with advanced clinical research sites.
Novotech made the announcement at the DIA conference (Booth 1904).
https://novotech-cro.com/welcome
Novotech Director of Business Development Barry Murphy who is attending the conference said: "Novotech has now signed five MOUs with medical institutions across the region with two more being signed in Thailand and the Philippines next month.
"Asia is the highest growth region for clinical research in the world, and as the Asia-Pacific CRO, we bring access to the key sites and KOLs to our clients via well-developed partnerships and relationships on the ground in Asia. Our MOUs further formalise these relationships.
"Some of the new MOUs are with the largest institutes in the region, such as the China Medical University Hospital in Taiwan which has more than a 2,000-bed facilities with dedicated clinical trials centres."
The partnerships are designed to give Novotech clients:
- Faster start-up times
- Access to significant patient database
- World-class clinical research - regulatory compliance with FDA, PMDA and EMEA
- Outstanding recruiters across many therapeutic areas: breast cancer, lung cancer, colorectal cancer, Hepatitis, SLE, RA, Stroke, Diabetes, etc.
- Leading principal investigators
The partnerships involve the provision of professional and medical clinical trial advice to the Novotech team including feasibility, principal investigator selection, and assistance with patient recruitment, while Novotech will promote the clinical research capabilities of these institutions internationally.
Novotech Executive Director, Asia Operations Dr. Yooni Kim said: "The partnerships mean Novotech has dedicated clinical experts within these leading hospital organisations to support and prioritise rapid clinical processes for Novotech biopharma clients.
"Novotech is the Asia-Pacific CRO, so is committed to establishing ongoing engagement with leading medical institutions in each country across the Asia-Pacific region. We have offices and teams on the ground as well as MOUs and long-term relationships with major hospitals that directly benefit our clients.
"Our in-country relationships enable a more comprehensive understanding of local regulatory changes, access to leading PIs, strong site connections, and productive patient populations to deliver success for our clients within timelines and budgets," Dr. Kim said.
Novotech is the Asia-Pacific specialist contract research organization (CRO) established in 1996, headquartered in Australia with offices in 11 countries across the region.
See the latest data on Asia clinical trials here:
http://www.novotech-cro.com/resources
.
About Novotech - www.novotech-cro.com
Headquartered in Sydney, Novotech is internationally recognised as the leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia Pacific presence includes running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners.
For RFP enquiries: see
https://novotech-cro.com/welcome
Novotech DIA Contact
Director of Business Development
Barry Murphy
Barry.Murphy@novotech-cro.com
USA: +1-415-527-8320
Media Contact
Susan Fitzpatrick-Napier
team@dmgpr.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
ASIA: +65 3159 3427
Source: Novotech Health Holdings Pte Ltd
Sectors: Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System
Mar 28, 2024 16:45 JST
Mitsubishi Logisnext Completes Demonstration of Automated Truck Loading, Leading to Start of Actual Operations in Japan
Mar 28, 2024 13:52 JST
Toyota Releases Sales, Production, and Export Results for February 2024
Mar 28, 2024 13:35 JST
TANAKA to Install 500 kW Fuel Cell System to Promote the Use of Hydrogen Energy at Production Plants
Mar 28, 2024 03:00 JST
PEVE to change name to TOYOTA BATTERY Co., Ltd. and produce batteries for a wide range of electric vehicles
Mar 27, 2024 15:13 JST
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy System
Mar 27, 2024 15:00 JST
TANAKA Holdings Announces Green Loan Financing for Construction of New Head Office Building
Mar 27, 2024 03:00 JST
JFE Steel and Hitachi Jointly Started Providing Solutions for the Steel Industry
Mar 26, 2024 19:04 JST
La Banque Postale and JCB join forces to elevate payments experience for travellers in France
Mar 26, 2024 15:00 JST
Fujitsu Tech Leverages AI and Underwater Drone Data for 'Ocean Digital Twin'
Mar 26, 2024 10:24 JST
NEC develops marketing strategy planning & effectiveness simulation technology using generative AI
Mar 25, 2024 10:08 JST
Toyota to Open New Tokyo Head Office in Shinagawa in FY2030
Mar 22, 2024 16:15 JST
Hitachi Selected as CDP Supplier Engagement Leader for the Third Consecutive Year
Mar 22, 2024 16:04 JST
Mitsubishi Motors Celebrates Production of 100,000th fully electric minivehicle
Mar 22, 2024 15:34 JST
JCB and AEON Credit Service Indonesia Launch the AEON JCB Precious Card
Mar 22, 2024 15:00 JST
JCB Issues White Paper on Calculating CO2 Emissions by Payment Method in Japan
Mar 22, 2024 12:00 JST
NEC and NTT successfully conduct first-of-its-kind long-distance transmission experiment over 7,000km using 12-core optical fiber
Mar 22, 2024 08:38 JST
Lifenet and Eisai Co-Develop Dementia Insurance "be"
Mar 21, 2024 17:36 JST
Toyota: Clarification of the Roles of and Expectations for Outside Executives, Revision of the Independence Assessment Criteria, and the Changes to Members of the Board of Directors and the Audit and Supervisory Board Members following the 120th Ordinary General Shareholders' Meeting
Mar 21, 2024 16:47 JST
Sales of Evolved GR Yaris to Start in April, While Purchasing Lotteries for WRC Driver-supervised Special Editions Start Today
Mar 21, 2024 16:31 JST
More Latest Release >>
Related Release
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
February 15 2023 09:00 JST
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
February 10 2023 19:00 JST
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
February 03 2023 13:00 JST
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
January 12 2023 15:00 JST
Novotech Acquires European CRO, Strengthens Global Operations
January 12 2023 15:00 JST
Novotech is Gold Sponsor at Biotech Showcase 2023
December 20 2022 11:00 JST
Data Shows 50% of New Trials Have Sites in Asia Pacific
December 15 2022 10:00 JST
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
December 06 2022 11:00 JST
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
November 11 2022 17:00 JST
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
October 25 2022 18:00 JST
More Press release >>